Europe’s leading psychedelic medicine conference, PSYCH Symposium, will return to London on December 4, 2025, bringing together scientists, clinicians, investors and policymakers to explore the future of psychedelic-assisted therapies. The event will take place at Conway Hall, co-organized by Prohibition Partners and Drug Science, with Psychedelic Health as a media partner.
Tickets and information are available at psychsymposium.com
After two sold-out editions in 2022 and 2023, PSYCH Symposium has established itself as the landmark European gathering for psychedelic medicine, focusing on evidence-based approaches to treating mental health disorders such as depression, anxiety, PTSD and addiction.
“We are amid a mental health crisis and our current treatments are failing millions,” said Prof. David Nutt, Professor of Neuropsychopharmacology at Imperial College London and Chair of Drug Science. “This event is critical because it shifts the dialogue on psychedelics from anecdote to evidence, offering a tangible pathway to what could be the most significant breakthrough in mental healthcare in half a century.”
The 2025 symposium will feature leading voices from science, healthcare, and policy, including:
- Prof. David Nutt – Imperial College London / Drug Science
- Jeff Smith MP – Co-chair, UK All-Party Parliamentary Group for Drug Policy Reform
- Prof. Celia Morgan – University of Exeter
- Dr. David Erritzoe – Imperial College London
- Dr. Anne Katrin Schlag – Head of Research, Drug Science
- Dr. Louise Paterson – Imperial College London
- Dr. Henrik Jungaberle – MIND Foundation
- Dr. Andrea Jungaberle – OVID Clinics
- Dr. Guy Goodwin – Chief Medical Officer, Compass Pathways
- Keith Abraham – CEO, Heroic Hearts Project UK
Sessions will cover the latest clinical findings on psilocybin, MDMA, ketamine and other compounds, alongside policy frameworks, investment trends, and ethical considerations in psychedelic therapy. The focus will be on shaping a responsible framework for the United Kingdom and the NHS.
“While other events discuss the global potential, this symposium is uniquely focused on building a responsible and effective framework for the United Kingdom,” added Prof. Nutt. “It’s where policymakers, clinicians, and investors will convene to design the future of psychedelic medicine within the UK’s specific regulatory environment.”
Stephen Murphy, founder and CEO of Prohibition Partners, said the event reflects the UK’s growing influence in the global psychedelic sector.
“Over the past three years, PSYCH Symposium has become the focal point for Europe’s psychedelic medicine sector, bringing together investors, regulators, researchers and clinical leaders,” Murphy said. “London continues to lead from the front. With world-class research institutions, a vibrant investment community and a growing demand for innovative mental health solutions, the UK is firmly at the centre of this rapidly evolving global movement.”
The psychedelic medicine market is projected to reach $3.8–4.6 billion globally by 2030, with Europe expected to grow from $340 million in 2024 to nearly $880 million by 2032.
PSYCH Symposium 2025 aims to highlight new clinical data, equitable access models and opportunities for collaboration across science, policy and industry.
